The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids
- 18 November 2013
- journal article
- research article
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (10) , 696-699
Abstract
This study shows that different approaches may be required to reduce unsanctioned use of different pharmaceuticals due to differences in how drugs are sourced. The data also highlight that plans to monitor only Schedule 8 benzodiazepines and prescription opioids may have limited effects on prescription opioid users who use non-prescribed sources and may represent a lost opportunity for reducing unsanctioned benzodiazepine use.Keywords
This publication has 20 references indexed in Scilit:
- The prescription drug epidemic in the United States: A perfect stormDrug and Alcohol Review, 2011
- Increasing deaths involving oxycodone, Victoria, Australia, 2000–09Injury Prevention, 2010
- Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical ManagementThe American Journal on Addictions, 2009
- Examination of opioid prescribing in Australia from 1992 to 2007Internal Medicine Journal, 2009
- The Impact of Benzodiazepine Use on Methadone Maintenance Treatment OutcomesJournal of Addictive Diseases, 2008
- Prescription opioid abuse among enrollees into methadone maintenance treatmentDrug and Alcohol Dependence, 2007
- Concurrent buprenorphine and benzodiazepines use and self‐reported opioid toxicity in opioid substitution treatmentAddiction, 2007
- The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS)Drug and Alcohol Review, 2005
- Prescription opioid abuse in patients presenting for methadone maintenance treatmentDrug and Alcohol Dependence, 2004
- Benzodiazepine use and HIV risk-taking behaviour among injecting drug usersDrug and Alcohol Dependence, 1992